The initial public offering market is stirring back to life, and the reflexive question from observers is whether we are witnessing another speculative bubble. The short answer: not even close.
After two years of near-paralysis in new equity issuance — a hangover from the 2021-2022 SPAC implosion and subsequent rate shock — underwriters are finally finding willing buyers for fresh stock. Technology names, in particular, have begun testing public appetite again, encouraged by stabilizing valuations and a Federal Reserve that has signaled it is done tightening. Yet the raw numbers remain modest by historical standards, and dramatically so when measured against the frenzy that preceded the 2000 crash.
The math doesn't lie
During the dot-com peak, hundreds of companies went public in a single year, many with negligible revenue and business models that amounted to little more than a domain name and a prayer. Retail investors lined up to flip shares on the first day of trading; institutional allocations were treated as guaranteed profits. The current environment is far more selective. Sponsors are pricing deals conservatively, often below initial ranges, and aftermarket performance has been mixed rather than universally euphoric. Investors burned by the 2021 vintage of money-losing listings are asking harder questions about unit economics and path to profitability.
Why caution persists
Several structural factors are keeping exuberance in check. Interest rates, though off their peaks, remain elevated compared with the zero-rate world that inflated private valuations for a decade. Private equity and venture capital firms sitting on aging portfolios would love to exit, but they are unwilling to accept the markdowns that public markets currently demand. Meanwhile, the broader equity indices have been choppy, with technology names in particular whipsawing on every inflation print and tariff headline. That is not the backdrop for a speculative stampede.
What to watch next
The second half of 2026 will be telling. A handful of large, well-known private companies are reportedly preparing S-1 filings, and their reception will set the tone. If buyers show up with enthusiasm, the backlog of deals waiting in the wings will accelerate. If not, sponsors will retreat again, and the revival will remain more headline than reality.
Our take
A functioning IPO market is a sign of health, not sickness. Companies need a path to public capital, and investors deserve access to growth stories earlier than the final liquidity event. The fact that this recovery is proceeding cautiously — with pricing discipline and skeptical buyers — is precisely what distinguishes it from the late-1990s casino. Wall Street's memory is short, but not that short.
